Xiaoran Wang, Xin Yu, Yong Wang, Jihu Lian, Zhenxiao Li, Chunli Dong, Haitao Song, Liangliang Zhang, Haitao Zhang, Yongjie Wang
{"title":"MicroRNA-18b-5p Inhibits the Malignant Progression of Prostate Cancer Through Downregulating TRAF5.","authors":"Xiaoran Wang, Xin Yu, Yong Wang, Jihu Lian, Zhenxiao Li, Chunli Dong, Haitao Song, Liangliang Zhang, Haitao Zhang, Yongjie Wang","doi":"10.2147/IJGM.S494962","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Extensive efforts have been made for translating the mechanisms of microRNAs (miRNAs) in prostate cancer (PCa). However, the specific role of miR-18b-5p in PCa is still in obscurity. Herein, miR-18b-5p/TRAF5 axis-oriented exploration in PCa has been launched.</p><p><strong>Methods: </strong>miR-18b-5p and TRAF5 expression in PCa tissues and cells was detected by RT-qPCR. <i>In-vitro</i> experiments were conducted to investigate the biological functions of miR-18b-5p and TRAF5 in PCa cells. The underlying mechanism of miR-18b-5p was revealed by luciferase reporter assay, miRNA Pull down, RT-qPCR, and rescue assay.</p><p><strong>Results: </strong>Lower miR-18b-5p and higher TRAF5 expression were observed in PCa tissues and cell lines. miR-18b-5p overexpression or TRAF5 downregulation impaired proliferation, diminished migratory and invasive properties, as well as advanced apoptosis in PCa cells. miR-18b-5p could regulate TRAF5 expression by directly binding to its 3'-untranslated region. Overexpression of TRAF5 abolished the suppressive effects of restored miR-18b-5p on PCa cell progression.</p><p><strong>Conclusion: </strong>This study elucidates that upregulated miR-18b-5p impedes PCa cell progression via downregulating TRAF5, which may provide a novel therapeutic basis for PCa.</p>","PeriodicalId":14131,"journal":{"name":"International Journal of General Medicine","volume":"18 ","pages":"1831-1843"},"PeriodicalIF":2.1000,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970425/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of General Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/IJGM.S494962","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Extensive efforts have been made for translating the mechanisms of microRNAs (miRNAs) in prostate cancer (PCa). However, the specific role of miR-18b-5p in PCa is still in obscurity. Herein, miR-18b-5p/TRAF5 axis-oriented exploration in PCa has been launched.
Methods: miR-18b-5p and TRAF5 expression in PCa tissues and cells was detected by RT-qPCR. In-vitro experiments were conducted to investigate the biological functions of miR-18b-5p and TRAF5 in PCa cells. The underlying mechanism of miR-18b-5p was revealed by luciferase reporter assay, miRNA Pull down, RT-qPCR, and rescue assay.
Results: Lower miR-18b-5p and higher TRAF5 expression were observed in PCa tissues and cell lines. miR-18b-5p overexpression or TRAF5 downregulation impaired proliferation, diminished migratory and invasive properties, as well as advanced apoptosis in PCa cells. miR-18b-5p could regulate TRAF5 expression by directly binding to its 3'-untranslated region. Overexpression of TRAF5 abolished the suppressive effects of restored miR-18b-5p on PCa cell progression.
Conclusion: This study elucidates that upregulated miR-18b-5p impedes PCa cell progression via downregulating TRAF5, which may provide a novel therapeutic basis for PCa.
期刊介绍:
The International Journal of General Medicine is an international, peer-reviewed, open access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treatment protocols. The journal is characterized by the rapid reporting of reviews, original research and clinical studies across all disease areas.
A key focus of the journal is the elucidation of disease processes and management protocols resulting in improved outcomes for the patient. Patient perspectives such as satisfaction, quality of life, health literacy and communication and their role in developing new healthcare programs and optimizing clinical outcomes are major areas of interest for the journal.
As of 1st April 2019, the International Journal of General Medicine will no longer consider meta-analyses for publication.